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Abstract 
 
Objective(s) 
The mitochondrial defects in Friedreich's ataxia have been reported in many researches. Mitochondrial DNA 
is one of the candidates for defects in mitochondrion, and complex I is the first and one of the largest 
catalytic complexes of oxidative phosphorylation (OXPHOS) system.  
Materials and Methods 
We searched the mitochondrial ND4L gene for mutations by TTGE and sequencing on 30 FRDA patients 
and 35 healthy controls. 
Results 
We found 3 missense mutations [m.10506A>G (T13A), m.10530G>A (V21M), and m.10653G>A (A62T)] 
in four patients whose m.10530G>A and m.10653G>A were not reported previously. In two patients, 
heteroplasmic m.10530G>A mutation was detected. They showed a very early ataxia syndrome. Our results 
showed that the number of mutations in FRDA patients was higher than that in the control cases (P= 0.0287). 
Conclusion 
Although this disease is due to nuclear gene mutation, the presence of these mutations might be responsible 
for further mitochondrial defects and the increase of the gravity of the disease. Thus, it should be considered 
in patients with this disorder.         
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Introduction 
Friedreich's ataxia (FRDA) is the most 
common inherited ataxia. In whites, it affects 1 
in 50,000 people (1). Clinically, FRDA is 
characterized by progressive spinocerebellar 
ataxia, diabetes mellitus, and hypertrophic 
cardiomyophathy (2). Friedreich's ataxia is 
caused by a GAA-trinucleotide expansion in 
the frataxin gene located on chromosome locus 
9q13, resulting in a reduced expression of 
frataxin, a small mitochondrial protein (3, 4). 
Owing to the mitochondrial localization of 
frataxin, the neurological and cardiological 
degenerations observed in FRDA are thought 
to be the result of a mitochondrial defect (5). 
NADH ubiquinone reductase (complex I) is 
the first and one of the largest catalytic 
complexes of oxidative phosphorylation 
(OXPHOS) system. Defects of this complex 
either alone or in combination with other 
complexes are probably the most frequently 
observed defect in the respiratory chain (RC). 
This predominance of complex I dysfunction 
suggests that its structure or function is 
relatively easily perturbed (6). Dysfunction of 
the mitochondrial RC is seen in patients with 
neurological diseases including alzheimer 
disease (AD) (7), parkinson disease (PD) (8), 
Multiple sclerosis (MS) (9, 10), and 
Friedreich’s ataxia (FRDA) (11). We 
suggested previously that our patients had a 
biochemical defect in complex I activity and 
ATP production (12) and several 
polymorphisms in mitochondrial ND genes 
(13). These findings prompted us to revisit our 
cases of Friedreich's ataxia. Although heart 
tissue was no longer the case, we investigated 
the mitochondrial ND4L gene in blood, and its 
mutations was assumed to be of special 
interest with regard to FRDA. 
 
Patients and methods  
Patients 
We studied thirty Iranian patients (14 females 
and 16 males) from unrelated families with a 
diagnosis of FRDA regarding their clinical 
aspects. We basically adopted the clinical 
criteria of Harding and Geffroy et al (1, 14). 
We also chose 35 healthy controls (16 females 
and 19 males) matched for age, sex, and 
ethnicity. All of the patients and the control 
group were informed of the aims of the study 
and gave their informed consents for the 
genetic analysis. 
 
Molecular analysis 
DNA was isolated from the peripheral blood 
samples using a DNA extraction kit (DNAfast 
Kit-Genfanavaran, Tehran, Iran). For ND4L 
gene amplification, PCR was carried out using 
DNA thermal cyclers (eppendorf, master 
cyclers, 5330) and ONP93 (5'-
TCTGGCCTATGAGTGACTAC-3') and 
ONP13 (5'-TTCACTGGATAAGTGGCGTT-
3') primers in 25 µl of a solution containing 
2.5 mM of MgCl2, 200 µM of each dNTP, 10 
pmol of each primer, 100 ng total DNA and 1 
U Taq DNA polymerase (Roche Diagnostics, 
Mannheim, Germany). The PCR reaction was 
performed for 30 cycles composed of the 
following steps: 95 ºC for 50˝, 60.5 ºC for 50˝, 
and 72 ºC for 35˝. For TTGE assay, PCR 
products (660 bp) were denatured at 95 °C for 
30 seconds and slowly cooled to 45 °C for a 
period of 45 min at a rate of 1.1 °C/min. TTGE 
was performed according to the manufacturer's 
instructions (Dcode Universal Mutation 
Detection Systems, BioRad, Hercules, CA). A 
volume of 10 µl of the denatured and 
reannealed PCR products was loaded on the 
gel. Electrophoresis was carried out at 140 V 
for 5-6 hr at a constant temperature increment 
of 1-2 °C/hr. The temperature range was 
determined by computer simulation (Win Melt 
software; Bio-Rad Laboratories).  
 
Analysis of secondary structure and 
pathogenicity prediction for amino acid 
changes 
The results of DNA sequence analysis were 
compared with those of the published 
Cambridge sequence (15). Each sequence 
variation was then checked against the 
Mitomap database (16). Those not recorded in 
the database were categorized as novel 
mtDNA variations. The conservation of the 
novel polymorphism bases was assayed using Mitochondrial Mutations in Friedreich's Ataxia  
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DNASTAR software (MEGALIGN program). 
This software was used to determine the DNA 
sequence alignment of the ND genes in humans 
and in other species (chimpanzee, bovine, horse, 
rat, gallus, and drosophila). 
The predicted amino acids sequence was 
analyzed using the FASTA program   
information system which is available at     URL: 
http://fasta.bioch.virginia.edu/fasta_www2/fasta_l
ist2.shtml. The secondary protein structure was 
analyzed by theoretical prediction using the 
algorithm of Garnier-Robson (17). A hydropathy 
plot of the amino acids sequence was calculated 
by the method of Kyte and Doolittle (18). 
The prediction of the pathogenicity of amino 
acids changes was accomplished by SIFT 
database at http://www.blocks.fhcrc.org. 
 
Statistical analysis 
Fisher’s exact probability test was used, and the 
values of P< 0.05 were regarded as statistically 
significant. The statistical analysis was 
performed using the GraphPad Prism software. 
 
Results 
The (GAA)n repeats of FRDA patients were 
observed in both alleles, ranging from 245 to 
991 GAA repeats. TTGE analyses for the 
mitochondrial ND4L gene were carried out on a 
total of 30 patients and 35 healthy controls. 
DNA fragments showing abnormal banding 
patterns on TTGE analysis were sequenced to 
identify the exact mutations (Figure 1). The 
analyzed mtDNA sequences were compared 
with those of the published sequence 
(MITOMAP 2009).  
We found three different types of point 
mutations in four of our patients and did not find 
any of these mutations in the healthy controls. 
The first mutation was m.10506A>G transition 
(homoplasmic state), changing a Thr codon 
(ACC) to Ala codon (GCC) at amino acid 
position 13 (designated T13A) in patient 1. It 
was previously reported in one LHON patient 
(19) and one PEO patient (20). SIFT predicted 
that the substitution at position 13 from T to A 
could be tolerated with a score of 0.10 and 
median sequence conservation of 3.64. 
 
 
 
Figure 1. The detection of heteroplasmic G10653A 
mutation by TTGE and sequencing. Lane 1 and 2, the 
heteroplasmic multi-band patterns belonging to FRDA 
patients. Lane 3, wild type. 
 
The second mutation was m.10530G>A 
transition, replacing a Val codon (GTA) with a 
Met (ATA) in a heteroplasmic state in patients 
2 and 3 (V21M). We found this mutation in 
patients 2 and 3 with about 60% heteroplasmic 
level, but the degree of heteroplasmic in their 
mothers  was  about  25%.  They  showed             
a very early ataxia syndrome, and other             
signs included diabetes mellitus and 
cardiomyopathy. The GAA expansion size in 
these patients was smaller than the mean GAA 
repeats in FRDA patients (651±220) (Table 1). 
The calculated chemical distance (D) between 
Thr and Ala was relatively large (D= 58) (21) 
and these mutations changed the hydropathy 
profile at a hydrophobic region (Figure 2). 
SIFT predicted that this protein function would 
be affected with a score of 0.00 for V21M, and 
the median sequence conservation was 3.64. 
  The  third  mutation  was  m.10653G>A 
transition (homoplasmic state), changing Ala 
codon (GCC) to Thr codon (ACC) at A62T in 
patient 4. The substitution at position 62 from 
A to T was predicted by SIFT to affect protein 
function with a score of 0.00. The results of 
amino acids alignment revealed that the 
mutations T13A, V21M and A62T were high, 
moderate, and low conserved, respectively. 
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Table 1. The summary of the clinical and genetic analysis of FRDA patients. 
Activity of complex I  
(nmol. Min
-1. mg protein
-1)* 
Novel/Reported  Heteroplasmic/ 
Homoplasmic 
Mutation  GAA 
repeats 
Age of 
onset 
Patient 
84.18  LHON, PEO  Homoplasmic  m.10506A>G  498  15  1  
67.44  Novel  Heteroplasmic  m.10530G>A  256  12  2 
78.53    Heteroplasmic  m.10530G>A  384  14  3 
81.45  Novel  Homoplasmic  m.10653G>A  247  21  4 
Mean value for the control subjects (n= 35) were 119.42±13.48 (mean±SD) (12). 
 
   
 
 
 
Figure 2. The hydropathy plot of the amino acids 
sequence of ND4L protein. The positive values indicate 
the hydrophobic regions, whereas the negative values 
indicate the hydrophilic regions. The arrows indicate the 
changes in hydrophobicity caused by the replacement of 
amino acids in the hydrophobic region. A) 10506,             
B) 10530 and C) 10653. 
 
Discussion  
Friedreich's ataxia is an inherited disease that 
causes a progressive damage to the nervous 
system resulting in symptoms ranging from 
gait disturbance and speech problems to heart 
diseases. Rotig et al, (1997) suggested that the 
frataxin gene plays a role in the regulation of 
mitochondrial iron content (22). They found a 
combined deficiency of a Krebs cycle enzyme, 
aconitase, and 3 mitochondrial respiratory chain 
complexes in the endomyocardial biopsy 
samples from patients with FRDA. Wilson and 
Roof (1997) suggested that mitochondrial 
dysfunction contributes to FRDA 
pathophysiology (23). Lodi et al (1999) reported 
in vivo evidence of impaired mitochondrial 
respiration in the skeletal muscles of FRDA 
patients (24).  
Therefore, pathogenic mtDNA mutations may 
be recognized as a secondary case and a 
predominant risk factor. ND4L protein is coded 
by mtDNA genome. It has 98 amino acids and is 
a transmembrane protein. The secondary 
structure prediction by the algorithm of Garnier-
Robson showed that this protein has a 79.3% 
alpha helix structure. We consider the m.10530 
G>A mutation pathogenic for a number of 
reasons. First, this mutation alters the residues in 
the sequence of the protein, which is moderately 
conserved during the evolution and is located in 
a structurally/functionally important region. If 
the site is conserved across species, this implies 
that it is functionally important, and a mutation 
at this site is likely to be deleterious. Second, the 
mutation is consistent with the biochemical 
defect because the patients had complex I 
deficiency in their lymphocyte cells (Table 2) 
(12). Third, this mutation is never reported as a 
neutral polymorphism and is not detected in 
normal individuals from different ethnic 
backgrounds. Fourth, the mutation is 
heteroplasmic in the lymphocyte cells analyzed 
(the degree of heteroplasmy was about 60%), 
and  heteroplasmic  is  a  common  feature              
of pathogenic mtDNA mutation. ForMitochondrial Mutations in Friedreich's Ataxia  
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Table 2. The results of the secondary structure prediction of three mutations on ND4L protein. 
 
ND4L  AA change  Alpha helix (%)  Extended strand (%)  Turn (%) 
 
Random coil (%) 
Normal - 79.3  26.8  11.0  2.4 
A10506G Thr  to  Ala  81.7  24.4  11.0  2.4 
G10530A  Val to Met  87.8  22.0  8.5  1.2 
G10653A Ala  to  Thr  70.7  34.1  11.0  3.7 
 
heteroplasmic mutations this means that 
affected individuals have a high percentage of 
mutated mtDNA, while unaffected individuals 
have a lower percentage. Fifth, the chemical 
distance of a valine amino acid from a 
methionine amino acid (V21M) is relatively 
large (D= 21). The more chemical distance 
shows, the more amino acids conservation. 
Sixth, SIFT predicted the affected protein 
function. SIFT is a sequence homology-based 
tool that sorts intolerant from tolerant amino 
acid substitutions and predicts whether an 
amino acid substitution in a protein will have a 
phenotypic effect. Seventh, this mutation 
caused to increase the alpha helix percentage 
to 87.8% (Table 2). Eighth, the mutation 
changes the hydropathy profile at a 
hydrophobic region (Figure 2). The changes in 
protein secondary structure and hydropathy 
profile might affect on protein function and be 
pathogenic. 
The homoplasmic m.10653G>A mutation has 
not been reported previously. We found this 
mutation in patient 4 that had a small expanded 
allele of 247 repeats. This patient had a severe, 
typical Friedreich's ataxia. Our present study 
indicates that these missense mutations might 
affect the function of the ND4L protein. Also, 
our result show that the number of mutations in 
FRDA patients is higher than that in the control 
cases (P= 0.0287). 
 
Conclusion 
Although, this disease is due to nuclear gene 
mutations, the presence of these mutations 
might be responsible for further mitochondrial 
defects and the increase of gravity of the 
disease. So it should be considered seriously in 
patients with this disorder.         
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